CARMUSTINE
IPI≥2
Fondazione Italiana Linfomi - ETSSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the IPI≥2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Fondazione Italiana Linfomi - ETS | Phase 3 | B |
Cyclophosphamide Fondazione Italiana Linfomi - ETS | Phase 3 | B |
Inno-206 Fondazione Italiana Linfomi - ETS | Phase 3 | B |
PREDNISONE TABLETS Fondazione Italiana Linfomi - ETS | Phase 3 | B |
Cytosin-Arabinosid Fondazione Italiana Linfomi - ETS | Phase 3 | B |
View all 10 →
Same molecule, other indications
CARMUSTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →